ScholarLens Back to search
2007•China Journal of EndoscopyRequires access

Transurethral plasmakinetic vaporization of prostate for treatment of benign prostate hyperplasia

Wang Li

Open publisher page 0 citations

Abstract

Objective To summarize the clinical experienec of transurethral plasmakinetic vaporization of prostate (TUPKVP). Methods 56 patients with symptomatic BHP were treated by TUPKVP. Results All patients were followed up of 1～12months postoperatively. The IPSS decreased from (26.3±3.1) to (8.5±0.6). The QOL decreased from (5.3±0.4) to (1.5±0.2). The Qmax increased from (8.2±2.3) mL/s to (18.5±2.5) mL/s. The PVR decreased from (165±35) mL to (10±2) mL. Conclusions It is suggested that TUPKVP is of efficacy,high safety and less complications.

About this research paper

What this paper is about

Objective To summarize the clinical experienec of transurethral plasmakinetic vaporization of prostate (TUPKVP). Methods 56 patients with symptomatic BHP were treated by TUPKVP. Results All patients were followed up of 1～12months postoperatively. The IPSS decreased from (26.3±3.1) to (8.5±0.6). The QOL decreased from (5.3±0.4) to (1.5±0.2). The Qmax increased from (8.2±2.3) mL/s to (18.5±2.5) mL/s. The PVR decreased from (165±35) mL to (10±2) mL. Conclusions It is suggested that TUPKVP is of efficacy,high safety and less complications.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To summarize the clinical experienec of transurethral plasmakinetic vaporization of prostate (TUPKVP). Methods 56 patients with symptomatic BHP were treated by TUPKVP. Results All patients were followed up of 1～12months postoperatively. The IPSS decreased from (26.3±3.1) to (8.5±0.6). The QOL decreased from (5.3±0.4) to (1.5±0.2). The Qmax increased from (8.2±2.3) mL/s to (18.5±2.5) mL/s. The PVR decreased from (165±35) mL to (10±2) mL. Conclusions It is suggested that TUPKVP is of efficacy,high safety and less complications.

Key concepts: Medicine, Prostate, Urology, Hyperplasia, Vaporization, Clinical efficacy, Surgery, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Transurethral plasmakinetic vaporization of prostate for treatment of benign prostate hyperplasia — Research Paper | ScholarLens